Advertisement
Singapore markets close in 46 minutes

  • Straits Times Index

    3,174.87
    -12.79 (-0.40%)
     

  • Nikkei

    37,068.35
    -1,011.35 (-2.66%)
     

  • Hang Seng

    16,239.14
    -146.73 (-0.90%)
     

  • FTSE 100

    7,831.73
    -45.32 (-0.58%)
     

  • Bitcoin USD

    64,933.58
    +3,995.29 (+6.56%)
     

  • CMC Crypto 200

    1,329.66
    +17.04 (+1.30%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • Dow

    37,775.38
    +22.07 (+0.06%)
     

  • Nasdaq

    15,601.50
    -81.87 (-0.52%)
     

  • Gold

    2,399.40
    +1.40 (+0.06%)
     

  • Crude Oil

    83.35
    +0.62 (+0.75%)
     

  • 10-Yr Bond

    4.6470
    0.0000 (0.00%)
     

  • FTSE Bursa Malaysia

    1,550.62
    +5.86 (+0.38%)
     

  • Jakarta Composite Index

    7,092.12
    -74.69 (-1.04%)
     

  • PSE Index

    6,443.00
    -80.19 (-1.23%)
     

TRACON to Report Third Quarter 2021 Financial Results and Company Highlights on November 3, 2021

TRACON Pharmaceuticals, Inc.
·2-min read

SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it will report its third quarter 2021 financial and operating results after the close of U.S. financial markets on Wednesday, November 3, 2021. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.

Conference call and webcast:

Date:

November 3, 2021

Time:

4:30 pm Eastern Time (1:30 pm Pacific Time)

Dial-in:

(855) 779-9066 (Domestic) or (631) 485-4859 (International)

Passcode:

4846079

Via web:

www.traconpharma.com; “Events and Presentations” section within the “Investors” section

A replay of the webcast will be available for 60 days on the website.

About TRACON

TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; YH001, a potential best-in-class CTLA-4 antibody in Phase 1 development; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S. To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com.

Company Contact:

Investor Contact:

Mark Wiggins

Brian Ritchie

Chief Business Officer

LifeSci Advisors LLC

(858) 251-3492

(212) 915-2578

mwiggins@traconpharma.com

britchie@lifesciadvisors.com